Potential Hepatoprotective Role of Galectin-3 during HCV Infection in End-Stage Renal Disease Patients

Figure 1

Serum values of biochemical parameters. Patients were divided into four groups: 40 patients with end-stage renal disease and hepatitis C viral infection (ESRD HCV⁺), 20 hepatitis C-positive patients (HCV⁺), 20 patients with end-stage renal disease (ESRD), and 20 healthy control individuals—normals (Nm). (a, b) Increased concentration of urea and creatinine in ESRD patients compared to healthy control as well as in ESRD HCV⁺ patients compared to HCV⁺ patients. (c) Significantly decreased concentration of aspartate aminotransferase (AST) in ESRD HCV⁺ patients in comparison to HCV⁺ patients. (d) Significantly decreased level of LDH in sera of ESRD HCV⁺ patients compared to HCV⁺ patients. Statistical significance was tested by independent samples t-test or Mann–Whitney rank sum test, where appropriate.

(a)

(b)

(c)

(d)